| __timestamp | Dynavax Technologies Corporation | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 1213000 |
| Thursday, January 1, 2015 | 22180000 | 3425000 |
| Friday, January 1, 2016 | 37257000 | 6311000 |
| Sunday, January 1, 2017 | 27367000 | 9518000 |
| Monday, January 1, 2018 | 64770000 | 28080000 |
| Tuesday, January 1, 2019 | 74986000 | 36550000 |
| Wednesday, January 1, 2020 | 79256000 | 46125000 |
| Friday, January 1, 2021 | 100156000 | 68486000 |
| Saturday, January 1, 2022 | 131408000 | 92032000 |
| Sunday, January 1, 2023 | 152946000 | 117532000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of companies is crucial. Over the past decade, from 2014 to 2023, Dynavax Technologies Corporation and Rhythm Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Dynavax, with a consistent upward trend, saw its SG&A costs rise by approximately 760%, peaking at $153 million in 2023. This reflects their aggressive expansion and marketing strategies. In contrast, Rhythm Pharmaceuticals, starting with a modest $1.2 million in 2014, experienced a staggering increase of nearly 9,600%, reaching $117 million by 2023. This surge underscores their rapid growth and increased market presence. Such financial insights not only highlight the companies' operational strategies but also provide investors with a clearer picture of their fiscal health and future potential.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.